These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

488 related items for PubMed ID: 16860259

  • 1. The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.
    Rajagopalan R, Xu Y, Abbadessa M, Quartet Study Group.
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):123-33. PubMed ID: 16860259
    [Abstract] [Full Text] [Related]

  • 2. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [Abstract] [Full Text] [Related]

  • 3. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.
    Mattoo V, Eckland D, Widel M, Duran S, Fajardo C, Strand J, Knight D, Grossman L, Oakley D, Tan M, H6E-MC-GLAT study group.
    Clin Ther; 2005 May; 27(5):554-67. PubMed ID: 15978304
    [Abstract] [Full Text] [Related]

  • 4. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinni MN.
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [Abstract] [Full Text] [Related]

  • 5. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL, Stewart J, Issa M, Lake B, Melis R.
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [Abstract] [Full Text] [Related]

  • 6. [Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus].
    Rodríguez A, Reviriego J, Polavieja P, Mesa J.
    Med Clin (Barc); 2008 Nov 29; 131(19):721-30. PubMed ID: 19091199
    [Abstract] [Full Text] [Related]

  • 7. Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.
    Rodríguez A, Reviriego J, Karamanos V, del Cañizo FJ, Vlachogiannis N, Drossinos V, ECLA Study Group.
    Cardiovasc Diabetol; 2011 Feb 11; 10():18. PubMed ID: 21314919
    [Abstract] [Full Text] [Related]

  • 8. Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus.
    Rajagopalan R, Perez A, Ye Z, Khan M, Murray FT.
    Drugs Aging; 2004 Feb 11; 21(4):259-71. PubMed ID: 15012171
    [Abstract] [Full Text] [Related]

  • 9. [Pioglitazone hydrochloride monotherapy or in combination with sulfonylurea therapy improves glycemia control in patients with type 2 diabetes].
    Yu Y, Li Y, Fan J, Wang Y, Yu H, Wang C, Liao Z, Gao H, Zhao W.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan 11; 34(1):117-20. PubMed ID: 15600200
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
    DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE.
    J Clin Endocrinol Metab; 2012 May 11; 97(5):1615-22. PubMed ID: 22419732
    [Abstract] [Full Text] [Related]

  • 11. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.
    Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH, QUARTET Study Group.
    Diabetes Care; 2004 Jan 11; 27(1):141-7. PubMed ID: 14693980
    [Abstract] [Full Text] [Related]

  • 12. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.
    J Clin Pharm Ther; 2006 Aug 11; 31(4):375-83. PubMed ID: 16882108
    [Abstract] [Full Text] [Related]

  • 13. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).
    Raskin P, Matfin G, Schwartz SL, Chaykin L, Chu PL, Braceras R, Wynne A.
    Diabetes Obes Metab; 2009 Jan 11; 11(1):27-32. PubMed ID: 17941873
    [Abstract] [Full Text] [Related]

  • 14. Clinical evaluation of combined therapy for type 2 diabetes.
    Rodríguez A, Ciprés L, Tofé S, Polavieja P, Reviriego J.
    Curr Med Res Opin; 2010 May 11; 26(5):1171-83. PubMed ID: 20297952
    [Abstract] [Full Text] [Related]

  • 15. Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome.
    Lester JW, Fernandes AW.
    Int J Clin Pract; 2005 Feb 11; 59(2):134-42. PubMed ID: 15854187
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
    Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P, Quartet [corrected] Study Group.
    J Clin Endocrinol Metab; 2004 Dec 11; 89(12):6068-76. PubMed ID: 15579760
    [Abstract] [Full Text] [Related]

  • 17. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
    Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE, Pioglitazone 026 Study Group.
    Coron Artery Dis; 2001 Aug 11; 12(5):413-23. PubMed ID: 11491207
    [Abstract] [Full Text] [Related]

  • 18. Differential regulations of lipid profiles between Japanese responders and nonresponders treated with pioglitazone.
    Kutoh E.
    Postgrad Med; 2011 Jan 11; 123(1):45-52. PubMed ID: 21293083
    [Abstract] [Full Text] [Related]

  • 19. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
    Herz M, Johns D, Reviriego J, Grossman LD, Godin C, Duran S, Hawkins F, Lochnan H, Escobar-Jiménez F, Hardin PA, Konkoy CS, Tan MH.
    Clin Ther; 2003 Apr 11; 25(4):1074-95. PubMed ID: 12809958
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
    Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, González JG, Chan M, Wolka AM, Boardman MK, DURATION-4 Study Group.
    Diabetes Care; 2012 Feb 11; 35(2):252-8. PubMed ID: 22210563
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.